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Abstract 
Clinical studies have indicated that in malignant surveillances fluctuations in the population of 
certain effector T-cell repertoire become suppressed. Motivated by such observations and in an 
attempt to quantify adaptive human response to pathogens, we define an immune response function 
(IMRF) in terms of mean square fluctuations of T-cell concentrations. We employ a recently 
developed kinetic model of T-cell regulation that contains the essential immunosuppressive effects 
of vitamin-D. We employ Gillespie algorithm to make the first study of fluctuations along the 
stochastic trajectories. We show that our fluctuation-based IMRF parameter can be more robust 
than using only the average value of T-cell concentration or ratio of different T-cell subsets. This 
function can differentiate responses of different individuals after pathogenic incursion both under 
healthy and disease conditions. We find that relative fluctuations in T-cells (and hence IMRF) are 
different in strongly regulated (malignant prone) and weakly regulated (autoimmune prone) 
regions. The cross-over from one steady state (weakly regulated) to the other (strongly regulated) is 
accompanied by a divergence-like growth in the fluctuation of both the effector and regulatory T-cell 
concentration over a wide range of pathogenic stimulation, displaying a dynamical phase transition 
like behavior. The growth in fluctuation in this desired (or, healthy) immune response regime (with 
high IMRF) is found to arise from an intermittent fluctuation between regulatory and effector T-
cells that results in a bimodal distribution of population of each, indicating bistability. The 
signature of intermittent behavior is further confirmed by calculating the power spectrum of the 
corresponding fluctuation of time correlation function. The calculated time correlation functions of 
fluctuations show that while the slow fluctuation causes the bistabilty in healthy state, the same 
fluctuation relaxes, in contrast, at relatively faster rate in disease states.  Dimmed fluctuations 
(equivalent to lower IMRF) can indeed be a characteristic feature of the strong or weakly regulated 
states. Thus, in diseases diagnosis process, such steady state response parameters can provide 
immense information which might become helpful to define an immune status. 
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I.  Introduction 
We scarcely realize that we are alive because inside our body there is a constant, highly 
vigilant microscopic mechanism designed to defend us every moment from millions of bacteria, 
microbes, viruses, fungi, parasites and pollutions. This amazing protection mechanism is called 
the immune system. It is indeed extremely efficient machinery that consists of a highly complex 
network involving billions of immune components and their interactions and chemical reactions. 
However efficient it is, depending on the type of perturbation, it often falls short that leads to a 
disease condition 1.  As a result we require external treatment to cure the disease.  Hence it is 
rather important to diagnose what is the disease condition and what could be the suitable 
marker/s for in the diagnostic treatment.   
Despite its importance, our understanding of human immune response has remained 
rather rudimentary. While there do exist clinical observations and systematic experimental 
studies that can help us identifying some of the essential immune ingredients and their functions 
2-13, we often fail to quantify immune responses because we lack specification of sensitive order 
parameters that can characterize state of immunity and foretell the onset of disease. Instead, the 
standard practice is to look for the average values of a number of immune components and opt 
for their values in the standard range as signatures of healthy system.  Often serious malfunction 
of the immune system develops over a period of time when average values remain within the 
range prescribed and may thus fail to give any indication of the impending crisis. Even more 
concerning is the fact that we take note only when the parameters have already entered the 
disease condition.  
3 
 
 Additionally, one should remember that our immune response is not only highly case 
(that is, disease) specific but is also personalized. It not only depends on external factors like 
pathogenic strength, pollution, etc. but also on internal individual immune tolerance 14-16. 
Therefore, we need to quantify immune response in terms of a suitable order parameter so that 
clinical diagnosis can more sensitively probe and foretell a disease condition. Before 
characterizing an appropriate marker we need to know some essential information in the 
regulation of immune response.            
To overcome the onslaught of innumerable types of ever-evolving pathogens, some immune 
cells having unlimited repertoire of receptors ensure that the invading pathogens are recognized 
17-20. After the antigen-specific recognition by receptors on lymphocytes, the clonal expansion of 
pathogen-specific lymphocytes (in brief, specific effector T-cells), directly or indirectly clear the 
pathogen load. Since the receptors are generated in a random process, these effector immune 
cells often fail to distinguish self from non-self. As a result, it leads to a serious threat to health 
which is the development of autoimmunity 20-23. A crucial prerequisite is the elimination of such 
self-reactive receptors by the mechanism of self-tolerance 14-16. 
Although both genetic and environmental factors affect disease prevalence, autoimmunity is 
primarily driven by the enhanced population of Th1 helper cells that attack various self-tissues in 
the body 24, 25. A number of other effector T cell subsets, like Th17 and Th9 cells, and regulatory 
T cells, like Tregs and Tr1 cells, also strongly participate in autoimmunity at cellular and 
molecular levels. Although IL-17 producing Th17 cells are believed to serve as one of efficient 
players in autoimmunity, the intricate balance between TRegs and Th17 cells, provide a basis for 
understanding the immunological mechanisms that induce and regulate autoimmunity 20. While 
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effector T cells control inflammation, regulatory T cells play a vital role to control it. Physicians 
usually treat autoimmune diseases with an immunosuppressive drug that decreases the activity of 
the effector T-cells so that it does not harm body’s own tissues or transplanted organs or tissues. 
Like corticosteroid medications, vitamin-D is also being exploited as an excellent immune 
modulator for the prevention of autoimmune disorders 26, 27.  
Overactive immune-suppression often may edit the immune response in such a way that 
malignant cells may find it relatively easier to evade the immune system 28-30. This immune-
evasion has been identified as a hall-mark on the onset of at least some types of cancer. Several 
reports documented that the progression of cancer is involved with an enhanced activity of 
regulatory T-cells and decreasing effects of effector T-cells 31-38. This enhanced activity of 
regulatory T-cells in presence of excess level of vitamin-D causes significant annihilation of 
effector T-cell population. Thus the opposing role of regulatory and effector T-cells in 
immunological activity often determine the strength of immune-regulation and the fate of a 
disease 20. The regulation is largely determined by the activation of APCs followed by the 
production of effector T-cells 39-43.    
Based on such T-cell response, we have categorized the regulation into three groups: (i) 
strong regulation, where the population of effector T-cell is less in comparison to the population 
of regulatory T-cell; (ii) weak regulation, where effector T-cells are larger in population than the 
regulatory T-cells; and (iii) moderate regulation where both effector and regulatory T-cells 
maintain a balanced population 44, 45.  We show below that the balance is maintained by a 
bistability. 
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In our earlier study we developed a coarse grained but general kinetic model in an 
attempt to capture the role of vitamin-D in immunomodulatory responses 44. We found that 
although vitamin-D plays a negligible role in the initial immune response, it exerts a profound 
influence in the long term, especially in helping the system to achieve a new, stable steady state. 
The study explores the role of vitamin-D in preserving an observed bistability in the phase 
diagram (spanned by system parameters) of immune regulation, thus allowing the response to 
tolerate a wide range of pathogenic stimulation which could help in resisting autoimmune 
diseases 44. 
To investigate the above mentioned regulation limits we have performed time evolution 
analysis of each participating element after the pathogenic attack to study their long time steady 
state behavior.  Most of the clinical and experimental studies use some standard values of 
effector and regulatory T-cell, more often the ratio of effector T-cells to TRegs as the predictor of 
patients’ immune profile 46, 47. However, such standardized ratios or numbers are frequently 
found to be challenged by other related studies or experimental results. Often we ignore that 
these standard numbers can be personalized and it may vary with patients even carrying the same 
disease. Under such circumferences both experimental and theoretical investigations should find 
suitable parameters that can quantify person specific immune response.  With such objective in 
mind, we develop and solve a coarse grained kinetic network model to probe and quantify the 
sensitive immune response.  In our model, person specific information enters through a set of 
rate constants (like production rates of effector and regulatory T-cells).  The state of a person’s 
immune system is also quantified by the concentration of inactive vitamin-D and other naturally 
occurring immunomodulatory chemicals/hormones and also concentration of native T-cells, 
among other things. Although varying within a range, these values differ from person-to-person. 
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It is difficult to get a detailed quantitative map of many of these parameters and also relationship 
of these values to the immune response function of an individual. A theoretical model can go a 
long way in understanding relationship between concentrations of various species and immune 
response. 
In many cases, a pre-disease condition may last for a long time. The average values of 
concentrations of lymphocytes (T-cells) may not offer any clue that a person is in the pre-disease 
condition. However, there may be certain other order parameters that may be able to capture the 
disease condition. We propose here and demonstrate that fluctuations of the T-cells can capture 
certain aspects of the pre-disease condition and can be a sensitive measure to follow. A brief 
concept of response functions that is associated with the fluctuation phenomena in this relation 
we discuss below. 
II.Theoretical description of immune response 
A. Definition of immune response in terms of fluctuations 
A response function provides a quantitative measure of the response of a system to 
external perturbation 48, 49.  In equilibrium statistical mechanics, such response functions are 
defined in terms of mean square fluctuations in the conjugate system properties 50-52. For 
example, specific heat is expressed in terms of mean square energy fluctuation, isothermal 
compressibility in terms of number density (or, volume) fluctuations, dielectric constant in terms 
of polarization (or, total dipole moment) fluctuations. The reason for these relations between 
response functions and fluctuations is that the latter provides the ability of the system to absorb 
external perturbation. In the case of time (or frequency) dependent perturbation, the response 
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also becomes time or frequency dependent. There is an intimate relation between the time 
dependent response function and a dynamical property of the system at equilibrium. This relation 
is expressed by linear response theory (LRT), first clearly formulated by Kubo in 1957 50.  
 
Kubo’s landmark analysis of response function starts by splitting a Hamiltonian ( )H  into an 
unperturbed 0( )H  and a time-dependent perturbation ( )H t′  
0 ( )H H H t′= +                                                                                                                        
Let us consider an isolated system and its Hamiltonian is denoted by H . The dynamical motion 
of the system determined by H is called “natural motion” of the system 53. We suppose that an 
external force ( )F t is applied to the system, the effect of which is represented by the perturbation 
energy, 
( ) ( )H t AF t′ = −                                                                                                                                       
where A  is a dynamical variable that is conjugate to field F. For example, as we just mentioned 
that if ( )F t is an electric field, then A can be the total dipole moment of the system. Similarly, if 
( )F t  is pressure, then A should be the volume 54.  
We generalize the above concepts to define an immune response for a living system. In our 
case the external perturbation is provided by the pathogen and the conjugate property is the T-
cell concentration that couples to pathogen invasion. Therefore, we define the first immune 
response function (IMRF) in terms of effector T-cell concentration, defined as  
Immune response, 
2( [ ( , )])
( , )
[ ( , )]
T i j
IMRF i j
T i j
δ
=  
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where [ ( , , )] [ ( , , ) ( , ) ]T i j t T i j t T i jδ = − . Here we assume T cell concentration is a function 
of i and j where i represents an individual and j represents a disease.   
We note that our system is not an equilibrium system. However, the system does attain a 
steady state, even in the presence of pathogenic load.   
  
B. Source of fluctuations 
 Let us consider a small volume element in our body, either in a blood sample or in a 
tissue. We consider that in that volume element there is initially only one pathogen and a certain 
number of native T-cells that on appropriate signal reception can convert into effector or 
regulatory T-cells. We also assume a fixed number of antigen presenting cells (APC) that in the 
presence of pathogen activates native T-cell. 
As stated, there is only one pathogen at time t=0 in our volume element.  Subsequent time 
evolution of pathogen concentration depends on various factors. (i) The rate of production of 
pathogen which varies from pathogen to pathogen. (ii) Efficiency of APC to detect and activate 
native T-cells into effector T-cells. (iii) Efficiency of the effector T-cells in destroying 
pathogens, (iv) generation of regulatory T-cells that involves again APC and also vitamin D, for 
example.  These efficiencies are reflected in certain rate parameters that are different from 
person-to-person.  
It is not emphasized sufficiently that while the rate parameters are characterized by an average 
value but also by a distribution. Thus, even when we start with fixed initial concentration, time 
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evolution gives rise to trajectories that can be different in different trials. That is because 
distribution in rates brings in a distribution of the concentration of active participants. 
Even when rate constant is kept fixed, there is fluctuation due to stochasticity of the type 
envisaged in Gillespie algorithm. This is the stochasticity inherent in a bimolecular reaction. In 
a coupled system of non-linear equations, such fluctuations can get enhanced near a dynamical 
crossover. It is noteworthy that while internal spontaneous statistical fluctuations depends on 
the system's state, the effect of external fluctuations is much more profound and modifies 
completely the domain in which a phase transition occurs. More about the implications of such 
microscopic fluctuation are discussed in the result section. 
 
C. Time dependence of immune response 
If one considers a time dependent change in the concentration of T-cell then one can write a 
time dependent response as,  
 [ ][ ]
0 0
( , , ) ( , , ) ( , , )
t t
IMRF i j t d t d t T i j t T i j t′ ′′ ′ ′′= ∫ ∫  
The quantity [ ][ ]( , , ) ( , , )T i j t T i j t′ ′′ is an example of time correlation function 53, 54.  This 
quantity measures the degree of correlation in steady state value of T-cell at two different times,  
t′  and t′′ .  
All these response functions we desire to calculate from a stable kinetic network model of T-cell 
regulation that we developed in our early work 44.   
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D. Quantification of immune response function (IMRF) : Connecting series 
of events  
The important constituents of the model are the following: (i) pathogen (it is important to 
note that, in our analyses we have considered pathogen, as a numerical quantity “P” that is 
capable of eliciting T-cell mediated immune response), (ii) naive T-cell, (iii) myeloid dendritic 
cell in the form of professional antigen presenting cells (APC), both in their resting (immature) 
and activated (mature) forms (iv) effector and regulatory T-cells, (v) inactive vitamin-D 
(25(OH)D3) and active vitamin-D (1,25(OH)2D3). However the participants, such as vitamin-D 
receptor (VDR) and the enzyme 25(OH)D3-1α-hydroxylase (CYP27B1) that simultaneously 
convert inactive vitamin-D to active vitamin-D (1,25(OH)2 D)-VDR [D*-VDR] protein complex, 
are considered as implicit factors for activation of the required transcriptional motif 44.  
It is important to emphasize here that we have essentially combined three important 
experimental observations those include the essential features of the adaptive responses reported 
by (i) Powri and Maloy, 42 (ii) Jorge Correale et al. 37 and (iii) Lorenzo Piemonti et al.  43. In 
Figure 1 we have presented the complex interaction network model that comprises various 
components and their inter-relation and regulation involved in the immune system.  
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Figure 1: A schematic representation of adaptive immune responses in terms of cellular 
interactions including vitamin-D, based on some experimental results and clinical observations.     
In the scheme, the primary events are the following: (1) The main step is the annihilation of 
pathogen by effector T-cells. (2) In presence of pathogen, inactive APC becomes stimulated after 
pathogen recognition and form resting APC. (3) Resting APC is activated either by pathogen or by 
the presence of any effector T-cell 41, 42. (4) Activation of effector T-cells are initiated by these active 
APC. (5) Effector T-cells initiates the formation of active vitamin-D from its inactive form 36. (6) 
Resting APC and active vitamin-D both can stimulate the production of regulatory T-cell from its 
precursor 37. (7) Enhancement in the rate of production of effector T-cells is controlled by both 
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regulatory T-cells (TReg) and active vitamin-D 36. (8) In addition, vitamin-D and regulatory T-cell 
up-regulate the formation of more resting APC from active APC 43.  
 
The present approach of network kinetic model building bears strong resemblance to 
similar methods adopted earlier in the study of kinetic proof reading 55, 56 and also in enzyme 
kinetics 57-59. In all these studies, precise quantitative prediction is hindered by insufficient 
knowledge about the system parameters. Especially, the values of rate constants are often not 
available. This lacuna is indeed a source of serious problem not only in study of kinetic proof 
reading and enzyme kinetics but also, as we find here, in any theoretical investigation of 
immunology.  Finally, master equations involved in all such problems are solved by employing 
the method of mean first passage time 56, 60, 61, Gillespie algorithm or straight forward numerical 
integration. We adopt stochastic simulation approach by using Gillespie algorithm 62, 63. The 
coarse-graining of interaction network, development of the reaction scheme and the master 
equations are discussed in the following section.  
The values of parameters involved (rate constants and concentrations) may span a wide 
range, and can vary from disease to disease, and from person to person. Thus, a study of the 
response to the variation of the important parameters has been carried out. Such a study is clearly 
necessary in the present context. 
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III. Framework of kinetic model  
A. Coarse-grained reaction network model development 
In order to describe the complex interplay among different types of immune cells, 
pathogens and the modulatory role of vitamin-D, first we need to develop a simple coarse-
grained approach that can both be solved and understood. The complexity arises because of the 
large number of biochemical machineries in the human body that are strongly coupled with each 
other 64, 65.  Understanding the relationship between these different machineries involving 
different types of cell may ultimately require detailing at the molecular level. A simpler, albeit 
cruder version is proposed here that accounts for some of the complexities present at the 
molecular level by coarse-graining them at the cellular level (Figure 1). With this goal in mind, 
we perform model analyses of T-cell activation, deactivation and regulation, and establish 
connection with a few experimental results discussed below.  
(i)       Myeloid dendritic cells (also we call them as antigen presenting cell (APC)) 
present in different organs, are the key players involved in triggering the onset of an 
adaptive immune response. Upon maturation and pathogen presentation, these 
dendritic cells serve to activate naive T-cells into effector T-cells. In contrast, 
immature dendritic cells upon pathogen contact convert naive T-cells into regulatory 
T-cells in the absence of maturation signal 41, 42. 
(ii)        Effector T-cells release cytokines which upregulate the activity of 1α-
hydroxylase enzyme (CYP27B1), which in turn, induces the conversion of active 
vitamin-D from its inactive form. The extensive experimental study by Correale et al. 
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reported that CD4+ T-cells are capable of metabolizing 25(OH)-vitamin D to 1,25 
(OH)2-vitamin D, which again inhibits the function of T-cells 37. 
(iii)       Active form of vitamin-D, 1, 25(OH)2D3 [D*] modulates the immune response 
through the inhibition of DC differentiation and maturation into potent APC 43. 
(iv)       Increased production of [D*], directly inhibits effector T-cell [TEff] production 
and upregulates CD4+/CD25+/FoxP3+ regulatory T-cell [TReg] response. These TReg 
cells also efficiently inhibit TEff cells proliferation 34-37.  
 
Coarse-graining of the interaction network is accomplished by making several 
simplifying assumptions. They are as follows: 
 (a)  Th1, Th2 and Th17 cells are grouped together as effector T-cells. The detailed description of 
these T-cells is depicted in our previous work 44. That is, we assume that they act together, in a 
parallel fashion. 
(b) It is well established that the primary molecular action of 1,25(OH)2D3 is to initiate gene 
transcription by binding to VDR which is a member of the steroid hormone receptor superfamily 
of ligand-activated transcription factors. VDR therefore is an important factor in 1,25(OH)2 D3 
mediated functions. More detailed information about VDR can be found in ref 66 66. On the 
contrary, there are reports that 1,25(OH)2D3 also has rapid actions that are not essentially 
mediated through transcriptional events involving VDR. They are in fact membrane initiated 
actions 67.  In the present model we have not included the effect of VDR. We have only 
considered the production of active vitamin-D from its inactive form upon T-cell activation.  
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   (c) In tests, the inactive form of vitamin-D, 25(OH)D3, is generally used as an indication of 
vitamin-D status. However, in dendritic cells (DC) use of this precursor depends on its uptake by 
cells and subsequent conversion by the enzyme CYP27B1 into active [D*] 66.  [D*] has a tight 
control over the homeostatic production rate that auto-regulates its production, by directly 
upregulating the activity of the P450 cytochrome CYP24A1. In our model we have considered 
the steady state rate of inactive vitamin-D that found from experimental and clinical 
measurements while keeping the concentration of these enzymes as the implicit factors. 
In the present analysis we consider the following set of connected biological reactions. 
Most of them are catalytic reaction in terms of up-regulation or down-regulation.  
(1) The primary step is the annihilation of pathogen by effector T-cell. 
   ( ) ( )Eff killed EffPathogen P +Effector T-cell T P + T→                           (i)    
 (2) Production of effector T-cell requires the presence of active antigen presenting cell (APC). 
Active APC, on the other hand is produced by the following sequence of reactions. 1st resting 
APC forms through the interaction between inactive APC and pathogen.  
( ) ( )in ResInactive APC A + P Resting APC A + P→                                               (ii) 
(3) Further pathogenic contact and/or effector T-cell contact promotes the resting APC to turn 
out to be active APC. 
Res Act
Res Eff Act Eff
A +P A +P     
A +T A + T
→ 
 → 
                                                                        (iii)           
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(4) Then effector T-cell is produced by the interaction between precursor/naive T-cell with active 
APC. 
( ) ( )Na EffAct ActNaive T-cell T +Active APC A T + A→                      (iv)               
(5) Simultaneously inactive vitamin-D is transformed into active vitamin-D upon effector T-cell 
contact. 
( ) ( )in Eff EffInactive Vitamin-D +T ActiveVitamin-  D*D +TD →          (v) 
(6) Resting T-cells and vitamin-D, both can initiate the formation of regulatory T-cell from naive 
T-cell.  
( ) ( )
( ) ( )
Na Res Reg Res
gNa Re
Naive T-cell T + Resting APC A T + A
Naive T-cell T + Active Viatmin-D ** TD +D
→  
 
→  
               (vi)     
 (7) Both regulatory T-cell and active vitamin-D can suppress the production of effector T-cell to 
control the hyperactivity of the immune system.  
killed
Eff Eff
kill
Reg Reg
ed
Eff Eff
+T T      T T +
T T +D+D **
→
→
 
 
 
                                                        (vii) 
(8) The cycle is completed by the transformation of active APC to resting APC again by the 
same duo, TReg and D* which work at tandem. 
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Act Reg Res Reg
Act Res
A +T A T     +
+D
 
A +D* A *
 →
→

 
 
                                                             (viii)       
We now transform the above set of connected biochemical transformations into rate 
equations. They give rise to a chemical network. 
B. Master equations quantifying the reaction network dynamics 
Now, we make a few important assumptions before we set about writing the master 
equations. 
(i) Pathogen, inactive APC and naive T-cells, each has a birth rate which includes influx and 
proliferation rates and a death rate similar to decay which incorporates natural cell death. The 
death rate of each component is linear in its concentration. 
(ii) The transition probabilities are all assumed to be constant with time but may vary from 
system to system (i.e. here person to person) according to the condition applied.  
(iii) To scale the unit, here we assume that in absence of pathogen, hundred (average number of 
T-cells present in hundred nano-liter blood sample) precursor T-cells pre-exist in our volume 
element.   
The annihilation, recombination and catalytic reactions articulated above lead to the 
following set of coupled master equations. The equations are size-extensive.  Size extensibility is 
an important element of our model.  
P P P Eff
dP m P k T P
dt
σ= − −                                                                                                       (1) 
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in
A inp in a in
dA k A P m A
dt
σ= − −                                                                                              (2) 
Reg * *Res inp in ar Act aD Act rese Res Eff inp Res a Res
dA k A P k T A k A D k A T k A P m A
dt
= + + − − −  (3) 
Reg * *Act rese Res Eff inp Res ar Act aD Act a Act
dA k A T k A P k T A k A D m A
dt
= + − − −            (4) 
* *Na T an Act Na resn Res Na nD Na n Na
dT k A T k A T k T D m T
dt
σ= − − − −                    (5) 
Reg * *
Eff
an Act Na er Eff eD Eff e Eff
dT
k A T k T T k T D m T
dt
= − − −                                (6) 
Reg
* Reg*resn Res Na nD Na r
dT
k A T k T D m T
dt
= + −                                                             (7) 
in
D eD Eff in D in
dD k T D m D
dt
σ= − −                                                                                 (8) 
*
* *eD Eff in D
dD k T D m D
dt
= −                                                                                               (9) 
 
where the respective  terms denote the following quantities : 
 Xk → Transition probability rates (self-evident from equations) 
kσ → Production rate by body of component k ,  
 im  → Overall death rate of component i , 
 P → Concentration of Pathogen, 
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inA → Concentration of inactive antigen presenting cells without pathogen capture,  
ResA → Concentration of resting antigen presenting cells after pathogen capture, 
ActA → Concentration of activated antigen presenting cells after pathogen recognition and 
effector T-cell contact.   
 NaT  → Concentration of naive T-cells, 
EffT → Concentration of effector T-cells, 
RegT → Concentration of regulatory T-cells, 
inD → Concentration of Inactive form of Vitamin-D3 (1, 25(OH)D) in the body  
*D → Concentration of active form of Vitamin-D3 (1, 25(OH)2D) in the body  
 
That is, we have used the same letter to denote both the species and its concentration. This 
should not cause any confusion. 
 
C. System parameters and data analysis 
 A set of nine coupled differential equations is difficult to solve analytically. We obtain 
the time dependent concentrations of all the components involved in the scheme by employing 
the well-known stochastic simulation analysis proposed by Gillespie 62. Both the single 
molecular as well as ensemble enzyme catalysis have been studied following this method. All the 
results presented in this article are derived using stochastic simulation method. However, we 
have also verified the consistency of each result by using the direct deterministic approach which 
is easier to implement. 
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As already mentioned, here we have considered one hundred nano-litre volume of blood sample. 
In the absence of pathogen this blood sample effectively contains the steady state concentration 
of all the precursor cells 68-70. Since all the reactions are bimolecular, the volume dependence of 
the reaction is expected to be an issue.  Thus, we have kept fixed the box volume to one hundred 
nano-liter and all the rate constants are in the unit of per day.  
Furthermore, we have assumed that in the absence of antigen, hundred precursor T-cells can pre-
exist within this fixed volume (100 nano-litre), in accord with known experimental values 68, 69. 
These T-cells have a 1% turnover per day. Concentrations of pathogens and APCs are also 
normalized. The production rate and death rate of these components are so assigned that their 
steady state values become one. Other associated probabilities/rate constants of different reaction 
sets are used from early papers in this field 44, 45. However, for vitamin D, the production and 
mortality rate constants are calculated from their steady state concentration.  Other vitamin D 
related rate constants are treated as variable in our study, as we have no experimental data 
available for them. For successful implementation of such a model, we require estimates several 
rate parameters values. Unfortunately accurate values of some of these rate constants are very 
hard to determine. Such rate parameters depend on several factors and differ from species to 
species. So they do not have any specific standard value. For example, it would be quite difficult 
to determine the mortality rate of effector and regulatory T-cell as in the present model these rate 
parameters also include the proliferation rate along with their death rate. Moreover, the 
pathogenic stimulation could be of various ranges according to their strength (virulence) and 
pattern.  
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Hence the primary difficulty of any predictive theoretical research in this area is the 
absence of accurate values of rate constants/transition probabilities. In the present study we have 
employed the following approach to circumvent this difficulty.  (i) In some cases where values 
could be estimated from literature, we have used the known value and varied them over a range 
to check the sensitivity of results. (ii) In a few cases, order of magnitude estimates for values 
were employed 44. We also focused on exploring the phase diagram by varying some key rate 
parameters that are not known and looked for the optimum region where results are sensitive to 
the parameter space (given experimental and assumed values of the rate constants and 
concentrations). To this end, we have varied the rate constants over a significantly wide range.  
In addition, the concentration of precursor elements was normalized, so as to reflect manifold 
change in the production level. Taking typical values as mentioned below (see Table 1), the time 
evaluation of the system and other analyses are performed in the present work. Here we have 
used the standard definition of steady state, i.e.; when the concentration of different species is 
invariant with time (dc/dt=0). In particular, for stochastic simulation, a steady state is assumed to 
reach when the concentration of a species fluctuates around a mean value without any noticeable 
drift at long time. 
Table 1: Basic parameter values (*time duration is taken as “days”). 
Parameter Symbol Value 
Reproduction rate of 
pathogen Pσ  
1 
Death rate of pathogen 
Pm  1 
Birth rate of APC 
Aσ  0.2 
Death rate of APC 
am  0.2 
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Rate of pathogen killing by 
efffector-T cells Pk  
100 
Rate of APC activation by 
pathogen inpk  
Variable 
Rate of APC reactivation by 
effector T cells resek  
Variable 
Rate of APC inhibition by 
regulatory T cells ark  
10-1 
Rate of APC inhibition by 
active vitamin-D *aDk  
10-7 
Birth rate of naive T cells 
Tσ  
1 
Rate of differentiation of 
naive T cell to effector T cell 
induced by active APC 
ank  
1 
Rate of differentiation of 
naive T cell to regulatory T 
cell induced by resting APC 
resnk  
1 
Mortality rate of naive T 
cell  nm  
0.01 
Rate of inhibition of effector 
T cell by active vitamin-D *eDk  
0.001 
Rate of inhibition of effector 
T cell by regulatory T cell erk  
10 
Rate of decay of effector T 
cells em  
0.1 
Rate of regulatory T cell 
reactivation by active 
vitamin-D 
*nDk  
10-7 
Rate of decay of regulatory 
T cells rm  
0.1 
Production rate of inactive 
vitamin-D Dσ  
1 
Death rate of inactive 
vitamin-D Dm  10
-9 
Rate of reactivation of 
active vitamin-D induced by 
effector T cells 
eDk  10
-7 
Rate of deactivation of 
active vitamin-D *Dm  
10-2 
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IV.  Results 
         Personalized immune system is a responsive network of dynamical events. In our 
mathematical model these events are included through values of rate constants and initial pre-
existing concentrations of cells, like APC, naive T-cells, vitamin D concentration. These values 
characterize the person based diversity in immune system. Here we are interested to explore 
how different set of parameters control immune response to the invasion by antigens.   
A.  Immune response via T-cell fluctuations 
          A healthy immune system usually functions with a balanced regulation that maintains the 
population of effector T-cells at an appropriate level, adequate for the clearance of pathogens. 
The production of effector T-cells again depends on the APC activation process, controlled by 
the rate parameter of APC activation by pathogenic stimulation (kinp).  We have studied all the 
three regulation limits as mentioned before at different pathogenic stimulation (kinp).  kinp is an 
important rate parameter in our analysis, and in adaptive immune system. 
As discussed earlier, the most stable and safe physiological state is the moderately regulated 
regime. This state is balanced between the two states, both of which are undesirable. This 
balance is achieved via a bi-stability which may give rise to large fluctuations that can be 
harnessed for immune purpose, if and when needed. 
 There may be experimental evidence on the role of fluctuation in immune response. A recent 
study conducted with 20 healthy individuals after strenuous physical activity showed significant 
decrease in the CD4 lymphocyte count after the rest for 60 minutes. The baseline mean CD4+ T 
cell count in these individuals at 0 min was 1060x106/l which was found to decrease to 660x 
106/l after a rest for 60 minutes. Hence concentration of CD4+ T cells has been observed to 
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fluctuate significantly in a healthy system 71. Thus it is natural to assume that such variation is 
exploited in the immune response. 
In order to explore the T-cell population fluctuations in the three regulation regime as mentioned 
earlier, we monitor the quantity, 
2( [ ( , )])
[ ( , )]
T i j
T i j
δ
 varying the rate of pathogenic stimulation, kinp. 
In certain sense, this expression is the analog of the thermodynamic response given by the 
isothermal compressibility.  However, this response is calculated at the steady state condition 
achieved by a constant, small influx of pathogen.  
 It is observed that our system of equations display a rather sharp crossover from a strong to 
weak regulation as the magnitude of pathogenic stimulation (kinp) increases from a low value 
(see Figure 2). This crossover is a sensitive function of many parameters, notably the vitamin D 
concentration. At the crossing point, we observe a bistability in immune response. 
Each peak position in the curves forms the ridge shown in Figure 2. Relative fluctuations of T-
cells (both for effector and regulatory) exhibit a rapid (divergent-like) growth at a point near the 
bistable crossover region. From our results it seems that system requires relevant fluctuation at 
homeostasis.   
A recent clinical study has reported that the disease states in cancer patients both TEff mean 
frequency and its mean coefficient of variation are rather significantly reduced 71, 72. However 
this study did not find any such change in regulatory T-cell subset. Many other case studies show 
that cancer patients have a significantly higher frequency of regulatory T-cells. This signifies that 
the system is under strong regulation.  In 2012, a pilot study over a number of ovarian cancer 
patients revealed the increased levels of recently activated regulatory T-cell subsets with tumor 
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migrating ability (CD4+CD25hiFoxp3+CD127−CCR4+CD38+ cells) in those patients when 
compared to healthy participants 73. Such enhanced level of regulatory T-cells are largely found 
to be reluctant to being “re-set” to healthy control homeostatic levels even after the 
chemotherapeutic perturbation.  
In that relation, Figure 2 shows that not only under strong regulation limit, effector and 
regulatory T-cell fluctuations decrease at any disease state, whether it is cancer prone or 
autoimmune. We believe that due to the dearth of necessary fluctuations (especially under the 
strong regulation limit), regulatory T-cell frequency becomes highly resistant to being “re-set” to 
their normal homeostatic level in cancer patients, as indeed been observed in some cases. 
The present study suggests that not only the absolute values of the effector and regulatory T-cell 
populations are important, but their fluctuations are also important and independent measure of 
immune response system. 
Our results also clearly demonstrate that for such complex in vivo systems, the occurrence of 
instabilities and non-equilibrium phase transition phenomena cannot be reliably understood from 
a complete deterministic approach as such description completely ignores system’s inherent 
fluctuations.  The significance of critical fluctuations that abound in the vicinity of a critical 
point has been repeatedly highlighted in the study of phase transitions. Studies of such collective 
organizational phenomena often use the concept of scaling laws obeyed by thermodynamic 
observables close to second-order phase transitions. Strikingly, in the present case such soft 
fluctuations are too abundant that they may alter the nature of the immune regulation profoundly. 
More importantly, the system may use these fluctuations in immune response by undergoing 
phase transition into the other regulation phase. Nevertheless, it is important to note that except 
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some very sensitive order parameter, such isolated fluctuation is rather difficult to arrest in a 
number of order parameter profiles.    
 
Figure 2:  Relative fluctuation of T-cell population both for (a) effector and (b) regulatory subsets. 
Both show divergent-like behavior near the crossing of strongly and weakly regulated states. The 
crossing is marked by a black dashed line where mean population of effector T-cells (red solid line) 
triumph over the mean population of regulatory T-cells (green solid line). Basic value parameters 
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for this analysis are taken from Table 1. We perform this analysis in presence a standard level of 
vitamin-D (50nmol/L). Note the change in scale in the two panels.  
 
B.  Personalized immune response and tolerance 
              We have discussed earlier that the values of rate constants and pre-existing concentration 
of inactive cells like APC, naïve T-cells, and inactive vitamin-D together can determine the state 
of a person’s immunity and tolerance. The fact that vitamin D has been implicated as an 
important factor in several different autoimmune diseases suggests that vitamin D might be an 
essential element that normally participates in the control of self-tolerance. We show here that 
tolerance could be intimately connected with bistability of healthy immune system.  It is worth 
mentioning here that experimental observations related to self-tolerance also supports the 
emergence of bistability where the balanced co-existence of strong and weakly regulated 
immune response preserve in the system. Note that while vitamin-D assisted strongly regulated 
state critically boosts up system’s tolerance for a certain pathogenic stimulation, weak regulation 
instigated always acts against that pathogen.         
We have investigated variation of regulation that occurs in response to pathogenic stimulation in 
different immune profiles characterized by different levels of inactive vitamin-D. The results are 
shown in Figure 3. In this analysis we explore how the regulation changes from strong to weakly 
regulated states causing autoimmunity and escape tolerance. We find that at low concentration 
(below 50nmol/L) of vitamin-D, system is rather antagonistic towards pathogenic load which 
leads to a more steady state population of effector T-cells. However, in the presence of higher 
concentration (beyond 50-100nmol/L) of vitamin D as shown in Figure 3 we find a considerable 
enhancement of the tolerance level where system is rather generous to the pathogenic load by 
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suppressing the production of effector T-cell with substantial up-regulation of regulatory T-cell 
population.  
 We have monitored normalized mean square fluctuation in the autoimmune prone region and 
tolerant region. Here we consider a person having less inactive vitamin-D concentration. In that 
state the response of an immune system is expected to be different from the state where inactive 
vitamin-D concentration is sufficient. In our model study we indeed find the response defined in 
terms of fluctuation to diverge near the tolerance limit. However this divergent-like behavior in 
the mean square fluctuation for effector T-cell population starts to disappear as we increase the 
pre-existing concentration level of inactive vitamin-D. In contrast, such disappearance of 
divergent-like growth in the same response parameter for regulatory T-cell population is not 
significant even at higher vitamin-D level.  
   The present analysis reveals that the observed significant reduction of relative fluctuation of 
effector T-cell to be a more sensitive diagnostic target to quantify the immune response. The 
reduction is observed after pathogenic stimulation of a patient living with higher dose of vitamin-
D or any other immunosuppressant. Such higher dose of vitamin-D induced immunosuppressive 
effect imitates the conditions of patients with gynaecological malignancies where the coefficient 
of variation of effector T-cell was found to be lower in cancer patients compared to healthy 
donors due to immune suppression 72.  On the contrary, for a patient having relatively lower dose 
of vitamin-D or any other analogue immunosuppressant, it seems that the relative fluctuation of 
both effector and regulatory T-cell may serve to be the efficient diagnostic parameters. But again 
the broader window in the divergence of effector T-cell fluctuation makes the effector cell 
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population fluctuation a more robust response parameter than the regulatory subset in such cases. 
Moreover, the result emphasizes the scope of diagnosis of a disease in a patient specific manner. 
 
 
 
 
Figure3: Vitamin-D induced enhancement of tolerance level (emergence of strong regulation). The 
black line separated orange zone corresponds to the tolerance, i.e. the system falls into the strongly 
regulated state where it can tolerate certain pathogenic load. Pink zone corresponds to the 
autoimmune prone region where the system falls into the weakly regulated state. Note that presence 
of 50-100 nmol/L inactive vitamin-D boosts up system’s tolerance. Vitamin-D dependence of 
immune response in terms of relative fluctuation of regulatory and effector T-cells population are 
measured along the tolerance and autoimmune prone regions. Relative fluctuation curves show 
divergent-like behavior near the tolerance limit. At high vitamin-D level (beyond 50-100 nmol/L) 
relative fluctuation of effector T-cell diminishes while the same for regulatory T-cell does not. At 
low vitamin-D level (below 50-100 nmol/L) relative fluctuation of effector T-cell has a much 
broader window of relative fluctuation than the same for regulatory T-cell.  Basic value parameters 
for this analysis are taken from Table 1. 
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C.  Bistablity and co-existence of steady state branches  
             In the light of our previous results, it is worth mentioning here that fluctuations are 
always present in cellular systems due to the stochastic nature of the elementary processes48. 
These fluctuations exert more profound effect and can induce new activities in small scale 
systems which may not be predicted or captured by any mean-field description or macroscopic 
rate laws. While noise, whether external or internal can cause a finite system to fluctuate 
between two stable states in bistable systems, macroscopic rate laws predict an asymptotic 
behavior that ignores such oscillations. Hence we need to understand the concept of bistability in 
the fluctuating environment as it is a basic phenomena of cellular functioning. In our model 
bistability is augmented in the system due the inhibitory effect of regulatory T cells on the 
activation of APC and effector T-cells. Furthermore, this augmentation is dependent on the level 
of vitamin-D. Interestingly, in the bistability condition system becomes more robust to tolerate 
significant changes of pathogenic stimulation. Here one typically finds strongly broadened 
probability distribution with a clear bimodal nature that is seen only in the vicinity of bistable 
point.  
 As mentioned, we find the occurrence of bistability in the moderate (that is, healthy) regulation 
regime through the coexistence of two stable steady states as shown in Figure 4. When such a 
system enters the bistable state with roughly equal levels of key determinants (in our case 
effector and regulatory T-cell populations), effects of stochastic fluctuation become amplified. It 
also depends on the external rate parameters which may enforce a final selection. As a result of 
these fluctuations, such complex biological systems may undergo modifications of their steady 
state properties. In particular, when the variance of fluctuations increases around a well defined 
mean value, transient phenomena appear which may absent in a typical bifurcation diagrams. 
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Hence the properties of the non-fluctuating systems may not be considered as a first 
approximation to the properties of the real system 48.   
 
 
 
Figure 4: Population distribution of effector (TEff) and regulatory (TReg) T-cells near bistable region. 
Both the T-cells show a clear bimodal distribution and are seen only in the vicinity of bistable 
region. The bimodal nature of the distribution corresponds to the existence of two stable states: 
weakly regulated state and strongly regulated state. We have normalized both the values of T-cell 
population by their respective max values for better comparison. kinp, krese are so chosen that they 
remain in the bistable region (kinp=0.1, krese =100; vitamin-D level ~ 50nmol/L). Other parameters 
remain unchanged as in Table 1. 
 
D.  Time-dependent oscillatory behavior o f antigen-specific effector (TEff) and regulatory 
(TReg) T cells and immune-suppressor dependence 
Whether the pathogenic stimulation strong or weak a healthy immune network always maintains 
a balanced regulation over the effector T-cell concentration to reduce the risk of autoimmunity or 
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cancer. However there are increasing evidences where to treat autoimmune patients, to transplant 
organ the applications of immunosuppressive drugs are emerging to a greater extent, sometimes 
without caring their plausible adverse effects. Such immunosuppressive drugs enhance the risks 
of malignancy, infection, cardiovascular disease and bone marrow suppression. Most importantly 
immunosuppressive and chemotherapeutic drugs at their high dose have a rather long term (in 
terms of years) effects and the adverse effects of these drugs may arise even long after the 
treatment has stopped 74-76.   
Here we find that the noise arising from T-cell dynamics could play an important role in 
controlling the bistablity in presence of pathogen. In particular, the cross-regulation of effector 
T-cells and regulatory T-cells generates a stable oscillatory dynamics that maintains body’s 
homeostasis. This dynamical cross-regulation has a clinical relevance in promoting the relapsing-
remitting events under autoimmune conditions.  We observe that the coupled oscillation of 
effector T-cells (TEff) and regulatory T-cell (TReg) initiates within 2-5 days and periodically 
continues (see Figure 3). It is important to note that their variations move in an anti-correlated 
fashion.  
In an interesting recent article Martinez-Pasamar et al. noted that the generation of an 
autoimmune response appears to be influences by the presence of susceptibility factors such as 
genetic polymorphisms, levels of modulators of the immune suppressors such as vitamin D, or 
previous infections that may change the thresholds of T-cell activation and differentiation, 
defining the autoimmune regime 77. To arrest the effects of immune modulators like vitamin-D 
we have introduced their important effects in our kinetic model. In our early study we have 
indeed showed for the 1st time that how the level of immune modulators like vitamin-D or any 
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other immune-suppressants can modify the immune regulation regime. In the present study, we 
use the same kinetic framework in an aim to address specific immune responses and the 
modulator dependence.  
 In Figure 5 we show a long time series demonstrating the dynamical pattern in the population of 
the two T-cells at three different concentrations of vitamin-D to monitor its dose dependent 
immunosuppressive effects.  The values of other parameters are kept fixed.  We observe that in 
the presence of optimal level of vitamin-D (50nmol/L), system remains in the bistable state 
where the frequent visits to both the  two regulation limits (strong and weak) are clearly reflected 
in the population dynamics of effector and regulatory T-cells (see Figure 5). In contrast, the 
system scarcely visits the weak regulation state when we increase the pre-existing level of 
vitamin-D to its higher dose (200nmol/L). However, when we set the pre-existing level of 
vitamin-D to a significantly lower value (10nmol/L), the system retains the weakly regulated 
state in most of the occurrences.  In fact, when the system tends towards a slightly weak/strong 
regulation regime from the bistable condition, we observe a less frequent dynamic cross 
regulation in the temporal progression of regulatory and effector T-cells populations. This could 
provide a dramatic signature of disease phenotype in clinical therapy 77, 78.  
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Figure 5:  Impact of vitamin-D over the dynamical profile of effector and regulatory T-cell in 
presence of pathogen. (a) In presence of optimal level of vitamin-D (50 nmol/L) system visits both 
the regulation states (weak and strong) quite frequently. Effector T-cells and regulatory T-cells 
propagate with an oscillation. Note the strong anticorrelated fluctuations between effector and 
regulatory T-cell subset and intermittency in the fluctuations of both species which are relevant for 
maintaining the bistability. (b) In presence of higher than optimal level of vitamin-D (200 nmol/L) 
system almost always resides in the strongly regulation state. (c) In presence of lower than optimal 
level of vitamin-D (10 nmol/L) system strongly avoids to be in the strongly regulation state. The 
pattern of such dynamical profiles has experimental and clinical relevance. The rate parameters 
considered here, are similar to Figure 4 given in main text. 
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E.   Relaxation behavior in healthy and disease states 
         By using the universality observed in critical phenomena it may be possible to provide 
quantitative predictions for the immunological condition of a given person by following the 
relaxation behavior 78, 79.  In the present case one can however perform a perturbation (pulse) 
experiment in situations where the immune system is (i) far from a transition (strong regulation 
and weak regulation) and (ii) in the case when the state is close to a transition (near bistable 
region). Such an “experiment” could clearly reveal the difference in time evolution leading to 
relaxation to its initial equilibrium state. The longer that time the system would take, the less 
stable is the system and thus we can assure that it is more close to a potential tipping point.  
          In Figure 6 (a) and (c) we observe the relaxation behavior of both effector and regulatory 
T-cell fluctuations respectively. In the present case we indeed find that the relevant properties of 
an immune system can be determined by the fluctuations of the order parameter. At bistable 
region their relaxation pattern shows critical phenomena like behavior. Relaxations in weak and 
strong regulatory regions also have their own characteristic features reflecting relatively faster 
decay.   
We recall Figure 5 where the temporal variation of the effector and regulatory T-cell near 
bistable region clearly exhibits intermittency. The signature of intermittent behavior can be 
confirmed by calculating the power spectrum of the fluctuation time correlation function (TCF)  
(TCF are shown in Figure 6(a) and (c)). Power spectrums of the fluctuation of the effector and 
regulatory T-cell are presented in Figure 6 (b) and (d) for the three regulation regime, i.e., 
strong, moderate and weak. The linear dependence of the power spectrum for a wide range of 
frequency starting from low frequency region with slope ∼−1 (in log-log plot) in the precise 
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regime of moderate and weak confirmed the strong intermittency present in the fluctuation for 
both effector and regulatory T-cell 78. However at the strongly regulated region the power 
spectrum only for effector T-cell shows a linear dependence at a rather higher frequency region, 
indicating the presence of small time scale intermittency in the fluctuations. Thus absence of 
intermittency in the fluctuation of the population of T-cells in the system may cause a weakening 
of immune response. Such anomalous response, in turn, may reflect symptoms of a particular 
disease.   
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Figure 6: Relaxation behavior and intermittency in the population fluctuation of effector and 
regulatory T-cell subset in strong, moderate and weak regulation zones respectively. (a) Time 
correlation function (TCF) of the fluctuation of effector T-cell population and (b) the power 
spectrum of the corresponding time correlation function for effector T-cell in log-log plot. (c) TCF 
of the fluctuation of regulatory T-cell population and (d) the power spectrum of the corresponding 
time correlation function for regulatory T-cell. For both types of T-cells, the associated TCFs show 
characteristic slow relaxation behavior at moderate regulation region. At strongly regulated region 
effector T-cell dynamics is considerable faster. Note the linear dependence over a wide range of 
frequency with slope ∼−1 (distinctive of 1/f noise) for both effector and regulatory T-cells at 
bistable and weakly regulated conditions, which confirms the large time scale strong intermittency 
in the fluctuations. The power spectrum for effector T-cell at strongly regulated region shows a 
straight line with slope ∼−1 that appears at much higher frequency ( ω ) range, which indicates the 
presence of intermittency in the short time scale.  
 
V.  Conclusion 
           In the present work we have attempted to provide a quantitative definition of personalized 
immune response of an individual human being to a given specific pathogen. We propose that 
personalized immune response can be quantified by an appropriate response function. Ideally, 
one should be able to categorize and quantify specific immune response so that appropriate 
preventive measures can be taken. The application of linear response theory, in this aspect, might 
be useful in the diagnosis of different stages of a disease in addition to the measurements of 
ratios or standardization of the concentrations of some potent cells or protein levels currently 
being advocated 72, 80, 81. 
We have followed methods of statistical mechanics in defining such individual-specific immune 
response functions. We propose that such response functions can be defined in terms of 
fluctuations of the relevant concentration of some key determinants. Progressive scientific 
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researches in the present field have evoked the idea of stochastic bifurcation with noise-induced 
bistability and its relevance towards nonlinear stochastic biochemical systems 80-82. Recently 
Qian et al. 85-87 analyzed a number of biochemical network models and showed that noise-
induced bistability in general arises from slow fluctuations, and a pitchfork bifurcation occurs as 
the rate of fluctuations decreases. Lefever et al. reported the importance of fluctuation 
modulating steady state properties of biochemical processes drastically and the related 
implications in tumor immunology 48, 49, 88.  
In the present study we have employed a chemical albeit simple network model of immune 
system to calculate the response from fluctuations of the effector T-cell concentration after 
pathogenic incursion. As this is coupled to regulatory T-cell concentration, we also calculate 
fluctuation in the regulatory T-cell concentration. The important outcome is that while absolute 
values of both the T-cell concentrations appear within the balanced range in an apparently 
healthy human being, fluctuations in the concentration of such cells show a divergent like 
behavior 72. Interestingly, both the two quantities show signatures at the boundary between 
strong and weak regulatory regimes. Fluctuation-driven  transitions  between  strong and  weakly 
regulated   branches are  found  to  occur  sufficiently  close  to  the  bifurcation  point. Thus 
sufficient reduction in fluctuation of a key determinant like effector or regulatory T-cell can be 
used to be an effective marker for defining a disease state.  
The fact that vitamin D has been implicated as an important factor in several different 
autoimmune diseases suggests that vitamin D might be an essential element that normally 
participates in the control of self-tolerance. However, we find that in the presence of vitamin D a 
considerable enhancement of the tolerance level which would lead to a reduced risk of 
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autoimmunity. We also monitor the effects of other susceptibility factors like levels of 
modulators of the immune response, such as vitamin D on the thresholds of T-cell population in 
the perspective of various autoimmune diseases.  For instance, we can consider a person having 
less inactive vitamin-D concentration. In that state the response of an immune system is expected 
to be different from the state where inactive vitamin-D concentration is sufficient. As a case 
study, we vary pre-existing inactive vitamin-D concentration in a wide scale from its standard 
homeostatic level. As a consequence we found a drastic reduction in effector T-cell fluctuation 
upon increased pre-existing vitamin-D level. The study also demonstrated that while the 
presence of optimal level of vitamin-D assists to broaden the tolerance range than its lower 
concentration limit, the range and intensity of essential fluctuation of effector T-cell 
concentration substantially falls down in the overdose limit.  The bimodal distribution, in 
presence of optimal concentration of vitamin-D, provides evidence of the fluctuation induced 
transition between strongly and weakly regulated states in bistable condition. To investigate the 
dynamical pattern near the  bistable condition and also at a condition  created by slightly shifting 
towards the extremes by varying doses of vitamin-D,  we observe less frequent visits of one of 
the stable states (than the other) during the infectious period at the disease states.  
 At the bistable condition, the strong anticorrelated fluctuations between effector and regulatory 
T-cell subsets and the associated intermittency in the fluctuations can be effectively used to 
probe both the disease phenotype and the response to immunotherapy. The power spectrum of 
the fluctuation time correlation function of T-cell dynamics reflects the intermittent behavior in 
their dynamics. The substantial faster decay in the relaxation mode of effector T-cell fluctuation 
at strongly regulated condition provides a marked signature of adaptive immune efficacy while 
we do not find such rapid drop in the relaxation of regulatory T-cell fluctuation. Such relaxation 
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behaviors show that fluctuation induced bistability arises from slow fluctuations, and bistabilty 
terminates as the rate of fluctuations decreases.  The broad fluctuation profile and significant 
reduction in the relative fluctuation of effector T-cell in the presence of the immune-modulator 
like vitamin-D suggest that the fluctuation of effector T-cell to be a more responsive one.   
Our model attempts to quantify a response parameter in terms of T-cell fluctuation. While steady 
state fluctuation of T-cells might help to evoke personalized immunization their characteristic 
dynamics indicates that some underlying processes are greatly randomized when birth or death 
occurs in large bursts. Each birth or death of immune component could involve several small 
steps, creating a memory between the individual events. We hope to identify some of those 
complex channels by addressing the temporal cooperatively involved in memory preservation in 
recent future.   
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